Across TCGA pan-cancer cohorts, AKR7L Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated AKR7L data layer compared with 22 for mass-spec protein.
The strongest signal is observed in bladder urothelial carcinoma (BLCA), where higher AKR7L Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated AKR7L expression acts as an unfavorable survival marker.
BLCA, HNSC, and OV are the cancer types where AKR7L Mutation most reproducibly stratifies survival.
Mutation survival associations by lineage
Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.